Skip to Content

Banu Arun, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1990 University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, MD

Postgraduate Training

1994-1997 Fellowship, Hematology and Oncology, Vincent T. Lombardi Cancer Center Georgetown University, Washington, DC, Edward Gelmann, Kevin Cullen
1991-1994 Residency, Internal Medicine, University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, Ugur Ulku
1990-1991 Internship, Internal Medicine, University of Istanbul, Cerrahpasa Medical School University Hospital, Istanbul, Turkey, Ugur Ulku

Selected Publications

Peer-Reviewed Original Research Articles
1. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. In Press. PMID: 23337751.
2. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-17, 2013. PMID: 23337751.
3. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. PMID: 22242911.
4. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347-55, 2012. PMID: 22270937.
5. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. PMID: 22392043.
6. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012. PMID: 22622473.
7. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J 18(3):261-6, 2012. PMID: 22583196.
8. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. PMID: 21913181.
9. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. PMID: 21761402.
10. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. PMCID: PMC3349074.
11. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun BK, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 132(3):1147-55, 2012. PMID: 22218884.
12. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blind, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res 5(9):1144-1154, 2012. PMID: 22827973.
13. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila) 5(2):276-82, 2012. PMID: 22102688.
14. de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: Implications for triaging of genetic testing. Hum Pathol 43(11):1932-1939, 2012. PMID: 22591913.

Grant & Contract Support

Title: Genetic risk prevention for breast cancer in primary care
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Duration: 12/1/2012 - 11/30/2014
 
Title: Advancing compliance in breast cancer risk-reduction strategies for underserved women identified with hereditary cancer syndromes
Funding Source: Avon Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2013
 
Title: Education and expansion of breast cancer genetic services to underserved populations in the Greater Houston area
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 4/1/2012 - 3/31/2013
 
Title: Education and expansion of breast cancer genetic services to understand populations in the Greater Houston area
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 8/1/2011 - 7/31/2013
 
Title: Adolescent's long-term adaption to familial cancer risks
Funding Source: Georgetown University
Role: Co-Investigator
Principal Investigator: Peterson
Duration: 12/1/2010 - 11/30/2013
 
Title: Zyflamend and breast health: MDACC
Funding Source: New Chapter Inc.
Role: Principal Investigator
Duration: 6/1/2010 - 6/30/2013
 
Title: Yoga for women with breast cancer undergoing radiotherapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Cohen
Duration: 4/1/2010 - 3/31/2016
 
Title: Development of novel early detection and prevention strategies for ER negative breast cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Principal Investigator
Duration: 9/25/2009 - 9/24/2014
 
Title: A phase I prevention study of Atorvastatin in women at increased risk for breast cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2003 - 3/31/2013
 
Title: Phase II study of Letrozole (Femara) plus Imatinib Mesylate (Gleevac) for postmenopausal patients with ER and/or positive metastatic breast cancer
Funding Source: Novartis
Role: Principal Investigator
Duration: 4/1/2003 - 12/31/2013

Last updated: 3/13/2013